Roche’s fenebrutinib is the first investigational medicine in over a decade that reduces disability progression in primary progressive multiple sclerosis (PPMS)

Late-breaking Phase III FENtrepid results presented at ACTRIMS show investigational fenebrutinib met its primary endpoint of non-inferiority compared to the current standard of care, OCREVUS, in ...

Ontario is proposing a new class of mutual funds. Investor advocates warn the risk may not be worth the reward

Doug Ford’s government is pushing regulators to give retail investors access to private assets such as real estate that can ...

F. Hoffmann-La Roche Ltd: Roche's fenebrutinib is the first investigational medicine in over a decade that reduces disability progression in primary progressive multiple ...

Late-breaking Phase III FENtrepid results presented at ACTRIMS show investigational fenebrutinib met its primary endpoint of non-inferiority compared to the current standard of care, OCREVUS, in reduc ...

Virtus Investment Partners, Inc. (NASDAQ:VRTS) Q4 2025 earnings call transcript

Virtus Investment Partners, Inc. (NASDAQ:VRTS) Q4 2025 Earnings Call Transcript February 6, 2026 Virtus Investment Partners, Inc. misses on earnings expectations. Reported EPS is $5.17 EPS, ...
Opinion

How Breaching 45-Day Exclusive Window Will Devastate Movies & Why Netflix's Commitment To Theatrical Is Misleading – Guest Column

Editor's Note: Joseph M. Singer is a producer/film financier and former studio executive and the founder of Elixir Media. He is Managing Principal/CEO of a company that specializes in M&A; he has ...